Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease
- 28 June 1999
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 270 (1), 45-48
- https://doi.org/10.1016/s0304-3940(99)00463-2
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatumNeuroscience Letters, 1998
- Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brainJournal of Neural Transmission, 1996
- Fetal nigral transplantation as a therapy for Parkinson's diseaseTrends in Neurosciences, 1996
- Functional recovery in parkinsonian monkeys treated with GDNFNature, 1996
- BDNF Enhances the Functional Reinnervation of the Striatum by Grafted Fetal Dopamine NeuronsExperimental Neurology, 1996
- Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patientsNeuroscience Letters, 1994
- Neurotrophic‐4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched culturesJournal of Neuroscience Research, 1994
- Brain‐Derived Neurotrophic Factor Protects Dopamine Neurons Against 6‐Hydroxydopamine and N‐Methyl‐4‐Phenylpyridinium Ion Toxicity: Involvement of the Glutathione SystemJournal of Neurochemistry, 1992
- BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigraNature, 1991
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976